Liver Cancer Targeting of Doxorubicin with Reduced Distribution to the Heart Using Hematoporphyrin-Modified Albumin Nanoparticles in Rats
Authors:
- 5 October 2011
- journal article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 29 (3) , 795-805
Abstract
To evaluate the usefulness of hematoporphyrin (HP)-modification of the surface of doxorubicin (DOX)-loaded bovine serum albumin (BSA) nanoparticles (NPs) in the liver cancer-selective delivery of DOX. HP-modified NPs (HP-NPs) were prepared by conjugation of amino groups on the surface of NPs with HP, a ligand for low density lipoprotein (LDL) receptors on the hepatoma cells. In vitro cellular accumulation of DOX, in vivo biodistribution of DOX, safety, and anti-tumor efficacy were evaluated for HP-NPs. Cytotoxicity and accumulation of DOX were in the order of HP-NPs>NPs>solution form (SOL). Cellular uptake from HP-NPs was proportional to the expression level of LDL receptors on the cells, indicating possible involvement of LDL receptor-mediated endocytosis (RME) in uptake. The “merit index,” an AUC ratio of DOX in liver (target organ) to DOX in heart (major side effect organ) following iv administration of HP-NPs to hepatoma rats, was 132.5 and 4 times greater compared to SOL and NPs, respectively. The greatest suppression of body weight decrease and tumor size increase was observed for iv-administered HP-NPs in tumor-bearing mice. HP modification appears to be useful in selective delivery of NP-loaded DOX to tumors.Keywords
This publication has 40 references indexed in Scilit:
- Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micellesJournal of Controlled Release, 2011
- 99mTc-hematoporphyrin linked albumin nanoparticles for lung cancer targeted photodynamic therapy and imagingJournal of Materials Chemistry, 2010
- Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancerBiomaterials, 2010
- PEGylated PLGA nanoparticles for the improved delivery of doxorubicinNanomedicine: Nanotechnology, Biology and Medicine, 2009
- Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancerAnnals of Oncology, 2006
- Paclitaxel-loaded poly(γ-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancerBiomaterials, 2006
- Porphyrin‐related photosensitizers for cancer imaging and therapeutic applicationsJournal of Microscopy, 2005
- Identification of 2-{2-[2-(5-Bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl}-4,5-dihydro-1H-imidazole (ML00253764), a Small Molecule Melanocortin 4 Receptor Antagonist That Effectively Reduces Tumor-Induced Weight Loss in a Mouse ModelJournal of Medicinal Chemistry, 2004
- Poly(l-glutamic acid)–anticancer drug conjugatesAdvanced Drug Delivery Reviews, 2002
- Nanoparticles in cancer therapy and diagnosisAdvanced Drug Delivery Reviews, 2002